Treatment Durability
Cross-source consensus on Treatment Durability from 1 sources and 6 claims.
1 sources · 6 claims
Uses
Risks & contraindications
Evidence quality
Other
Highlighted claims
- Treatment initiation, adjustment, and discontinuation will be recorded during follow-up. — Hongkou Advanced Research on Metabolism and Obesity iNtervention studY (HARMONY): a protocol for a longitudinal cohort study
- Responses to NuSH-based therapies vary substantially. — Hongkou Advanced Research on Metabolism and Obesity iNtervention studY (HARMONY): a protocol for a longitudinal cohort study
- More than 13% of semaglutide users and 9% of tirzepatide users in cited trials were non-responders. — Hongkou Advanced Research on Metabolism and Obesity iNtervention studY (HARMONY): a protocol for a longitudinal cohort study
- HARMONY examines uncertainties around low-dose GLP-1 receptor agonist use, flexible titration, reinitiation, and sustained weight control. — Hongkou Advanced Research on Metabolism and Obesity iNtervention studY (HARMONY): a protocol for a longitudinal cohort study
- About 47%–65% of people with overweight or obesity discontinue GLP-1 receptor agonist therapy. — Hongkou Advanced Research on Metabolism and Obesity iNtervention studY (HARMONY): a protocol for a longitudinal cohort study
- After semaglutide cessation, about 44% of patients regained at least 25% of lost weight within 1 year. — Hongkou Advanced Research on Metabolism and Obesity iNtervention studY (HARMONY): a protocol for a longitudinal cohort study